Balaxi Pharmaceuticals delivers strong growth in Q2 FY23

Revenue is up 23% whereas Profit After Tax expands 29% for the company

Sustaining growth momentum is key for Navin Fluorine: ICICI Securities

NFIL’s ambition is to reach revenues of US$100mn from CDMO by FY25.

Aragen to operationalize Hyderabad formulation manufacturing facility by Jan 2023

The new plant will include a wide range of dosage form capabilities for oral solids, liquids, topicals, films, and manufacturing technologies for granulation, film coating, spray drying, tableting

AGC begins study to expand its Bio-CDMO capability in Japan

Lupin receives warning letter from US FDA

The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility

CellOrigin Biotech collaborates with Qilu Pharma to develop CAR-iMAC Cell Therapy

Cipla receives EIR for Indore plant, Aurbindo for Raleigh

The plant at Raleigh, North Carolina, USA owned by Aurolife Pharma has received an establishment inspection report (EIR)

Everstone acquires controlling stake in Softgel Healthcare

Veda Corporate Advisors was the exclusive financial advisor to SHPL and its shareholders.

Panacea Biotec received US FDA communication for Baddi facility

The OAI classification implies that the USFDA expects further corrective actions and may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved

Lonza and Touchlight collaborate on end-to-end mRNA offering

Under the terms of the agreement, Lonza can now provide its customers with seamless access to Touchlight’s enzymatic DNA technology